Following a single intraperitoneal injection of alkylated 3-amino-6-phenylpyridazine, it suppressed DAPK-1 kinase activity and decreased brain tissue loss following cerebral ischemia in both acute and sustained brain injury models, suggesting that DAPK-1 inhibition may provide a new therapeutic approach to subdue early programmed cell death in acute brain injury [102]. Here, DAPK1 is linked to brain injury.